Spyre Therapeutics, Inc. (SYRE)

NASDAQ: SYRE · USD

$99.5

+0.42 (+0.4%)· Recorded snapshot

Market cap	9.3B
Net income (ttm)	-150.2M
EPS (ttm)	-$2.01
Shares out	93.5M
Volume	590,076
Beta	3.11

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -150.2M
EPS (ttm): -$2.01
Market cap: 9.3B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Держать

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-23

P25 n/aP50 n/aP75 n/a

ROIC-21.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All SYRE indicators

Market & fundamental data

Available fields

180

Groups with data

Currency

USD

Showing 180 of 180 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001636282
Company name	Spyre Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	00773J202
Earnings date	2026-11-10
Earnings time	amc
Employees	125
Employees change	38
Employees growth	43.68%
Enterprise value	$8.1B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2013
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2016-04-07
Is primary listing	Yes
Is SPAC	No
ISIN number	US00773J2024
Last 10-K release date	2026-02-19
Last earnings date	2026-08-04
Last refreshed	2026-10-28
Last stock split date	2023-09-08
Last stock split type	Reverse
Market cap	$9.3B
Market cap category	Mid-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$99.47
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	SYRE
U.S. state	Massachusetts
Website	https://www.spyre.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-2.02%
FCF / EV yield	-2.58%
FCF yield	-2.26%
P/B ratio	9.14x
Price / tangible book value	9.7x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.2M
ROA	-19.81%
ROA (5Y)	-34.32%
ROCE	-24.45%
ROE	-22.98%
ROE (5Y)	-111.46%
ROIC	-21.79%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	6
Net income growth quarters	1
Net income growth years	2
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	$-271.3M
EPS	$-2.01
FCF per share	$-2.24
Financing cash flow	$753M
Free cash flow	$-208.9M
Free cash flow minus SBC	$-254.6M
Gross profit	$-215.8M
Investing cash flow	$-463.7M
Net cash flow	$80.3M
Net income	$-150.2M
Operating cash flow minus SBC	$-254.6M
Operating income	$-271.3M
Stock-based compensation	$45.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$10.84
Debt / equity	0
Long-term assets	$0
Long-term liabilities	$8.6M
Net cash (debt)	$1.1B
Net cash / market cap	12.37%
Net cash growth	117.51%
Net debt / equity	-1.04
Piotroski F-Score	1
Shareholders' equity	$1.1B
Tangible book value	$954.7M
Tangible book value per share	$10.84
Total assets	$1.2B
Total cash	$1.1B
Total debt	$0
Total liabilities	$71.9M
WACC	21.34%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$1.2B
Current liabilities	$63.3M
Current ratio	18.53
Net working capital	$-35.6M
Quick ratio	18.23
Working capital	$1.1B

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-31.8%
Dividend yield	0%
Shareholder yield	-31.8%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-32.93%
10Y return CAGR	-3.92%
10Y total return	-32.93%
150-day SMA	$84.13
1D price change	0.42%
1M price change	14.96%
1M total return	14.96%
1W price change	7.78%
1W total return	7.78%
1Y price change	300.94%
1Y return CAGR	301.32%
1Y total return	300.94%
20-day SMA	$87.48
200-day SMA	$72.56
3M price change	-1.53%
3M total return	-1.53%
3Y price change	824.11%
3Y return CAGR	109.81%
3Y total return	824.11%
50-day SMA	$90.46
50-day SMA vs 200-day SMA	50over200
52-week high	$110.18
52-week high date	2026-08-19
52-week low	$21.15
52-week low date	2025-11-07
5Y price change	-47.18%
5Y return CAGR	-11.99%
5Y total return	-47.18%
6M price change	37.01%
6M total return	37.01%
All-time high	$318.75
All-time high date	2016-04-08
All-time low	$2.66
All-time low date	2023-06-21
Average true range (ATR)	$4.82
Average volume	1.4M
Beta (1Y)	2.28
Beta (2Y)	1.92
Beta (5Y)	3.11
Change from 52-week high	-9.72%
Change from 52-week low	370.4%
Change from all-time high	-69.09%
Change from all-time low	3,603.38%
Change from open	0.28%
Day's gap	0.14%
Dollar volume	$58.7M
High price	$100.00
Low price	$98.03
Monthly RSI	76.98
Open price	$99.19
Position in 52-week range	72.84%
Premarket change	-0.01%
Premarket close	$99.05
Premarket price	$99.04
Previous close	$99.05
Price vs 150-day SMA	17.1%
Price vs 20-day SMA	12.61%
Price vs 200-day SMA	35.76%
Price vs 50-day SMA	8.9%
Relative volume	0.42
RSI	63.28
Sharpe ratio	2.37
Sharpe ratio (3Y)	1.25
Sharpe ratio (5Y)	0.42
Sortino ratio	4.34
Sortino ratio (3Y)	2.07
Sortino ratio (5Y)	1.14
Volume	590.1K
Weekly RSI	62.07
YTD price change	200.7%
YTD total return	200.7%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	87.4M
Float percentage	93.56%
Shares change (QoQ)	7.87%
Shares change (YoY)	31.8%
Shares held by insiders	5.38%
Shares held by institutions	105.94%
Shares outstanding	93.5M
Short % of float	14.69%
Short % of shares	13.74%
Short ratio	9.9 days

Deeper analysis on SYRE

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this SYRE report

Is a complete SYRE research report available?

No complete published report is available for Spyre Therapeutics, Inc. (SYRE) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Spyre Therapeutics, Inc. (SYRE)

Price

Financial snapshot

Fair-value bridge

Latest news · SYRE

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All SYRE indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on SYRE

Frequently asked questions